Foghorn Therapeutics's EBIT per Share for the
three
months ended in Dec. 2023 was $-0.60.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.57.
During the past 3 years, the average EBIT per Share Growth Rate was 25.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -9.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Foghorn Therapeutics's EBIT per Share or its related term are showing as below:
FHTX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -26.9 Med: -6.8 Max: 25.4
Current: 25.4
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Foghorn Therapeutics was 25.40% per year. The lowest was -26.90% per year. And the median was -6.80% per year.
FHTX's 3-Year EBIT Growth Rate is ranked better than 77.05% of 1307
companies
in the Biotechnology industry
Industry Median: 3.4
vs FHTX: 25.40
Foghorn Therapeutics EBIT per Share Historical Data
The historical data trend for Foghorn Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foghorn Therapeutics (NAS:FHTX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Foghorn Therapeutics EBIT per Share Related Terms
Thank you for viewing the detailed overview of Foghorn Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Foghorn Therapeutics (Foghorn Therapeutics) Business Description
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FHTX has been successfully added to your 